Clinical Concerns of Immunogenicity Produced by Biopharmaceuticals

Clinical Concerns of Immunogenicity Produced by Biopharmaceuticals
Author: Tamilvanan Shunmugaperumal
Publisher: LAP Lambert Academic Publishing
Total Pages: 92
Release: 2010-09
Genre:
ISBN: 9783843356008

Download Clinical Concerns of Immunogenicity Produced by Biopharmaceuticals Book in PDF, Epub and Kindle

Following the administration of biopharmaceuticals into human body, the formation of antidrug or neutralizing antibodies and other general immune system effects (including allergy, anaphylaxis, or serum sickness) are of clinical concerns regarding therapeutic efficacy and patient safety. For example, drug-induced neutralizing antibodies to erythropoietin (EPO) result in pure red cell aplasia, whereas drug-induced/acquired anti-factor VIII antibodies worsen the pathology associated with hemophilia. The possible mechanism, prediction and reduction of immunogenicity produced by biopharmaceuticals are overviewed. This book encompasses the clinical concerns of immunogenicity produced by various biopharmaceuticals such as growth hormone, insulins, granulocyte-macrophage colony-stimulating factor, interferons, megakaryocyte differentiation and growth factor, EPO, factor VIII, factor IX, acid alpha-glucosidase and glatiramer acetate including their biosimilar versions wherever possible. With this coverage of very interesting informations, this book is an essential reference for researchers in pharmaceutical industry who develop biopharmaceutical products.

Immunogenicity of Biopharmaceuticals

Immunogenicity of Biopharmaceuticals
Author: Marco Weert
Publisher: Springer Science & Business Media
Total Pages: 269
Release: 2008-02-06
Genre: Medical
ISBN: 0387758410

Download Immunogenicity of Biopharmaceuticals Book in PDF, Epub and Kindle

Immunogenicity of Biopharmaceuticals is the first book to comprehensively address the potential of an immune response to biopharmaceuticals. It is intended to give a broad overview of the current state-of-the-art regarding this subject. The chapters range from an overview of the immune system and factors that may trigger the immune system, via detection of antibodies and clinical implications, to various case examples and the regulatory view on immunogenicity.

Statistical Methods for Immunogenicity Assessment

Statistical Methods for Immunogenicity Assessment
Author: Harry Yang
Publisher: CRC Press
Total Pages: 259
Release: 2015-07-17
Genre: Mathematics
ISBN: 1498700357

Download Statistical Methods for Immunogenicity Assessment Book in PDF, Epub and Kindle

Develop Effective Immunogenicity Risk Mitigation StrategiesImmunogenicity assessment is a prerequisite for the successful development of biopharmaceuticals, including safety and efficacy evaluation. Using advanced statistical methods in the study design and analysis stages is therefore essential to immunogenicity risk assessment and mitigation stra

Issues in Pharmacology, Pharmacy, Drug Research, and Drug Innovation: 2011 Edition

Issues in Pharmacology, Pharmacy, Drug Research, and Drug Innovation: 2011 Edition
Author:
Publisher: ScholarlyEditions
Total Pages: 4229
Release: 2012-01-09
Genre: Medical
ISBN: 1464963428

Download Issues in Pharmacology, Pharmacy, Drug Research, and Drug Innovation: 2011 Edition Book in PDF, Epub and Kindle

Issues in Pharmacology, Pharmacy, Drug Research, and Drug Innovation: 2011 Edition is a ScholarlyEditions™ eBook that delivers timely, authoritative, and comprehensive information about Pharmacology, Pharmacy, Drug Research, and Drug Innovation. The editors have built Issues in Pharmacology, Pharmacy, Drug Research, and Drug Innovation: 2011 Edition on the vast information databases of ScholarlyNews.™ You can expect the information about Pharmacology, Pharmacy, Drug Research, and Drug Innovation in this eBook to be deeper than what you can access anywhere else, as well as consistently reliable, authoritative, informed, and relevant. The content of Issues in Pharmacology, Pharmacy, Drug Research, and Drug Innovation: 2011 Edition has been produced by the world’s leading scientists, engineers, analysts, research institutions, and companies. All of the content is from peer-reviewed sources, and all of it is written, assembled, and edited by the editors at ScholarlyEditions™ and available exclusively from us. You now have a source you can cite with authority, confidence, and credibility. More information is available at http://www.ScholarlyEditions.com/.

Immune Aspects of Biopharmaceuticals and Nanomedicines

Immune Aspects of Biopharmaceuticals and Nanomedicines
Author: Raj Bawa
Publisher: CRC Press
Total Pages: 602
Release: 2019-01-10
Genre: Medical
ISBN: 1351399772

Download Immune Aspects of Biopharmaceuticals and Nanomedicines Book in PDF, Epub and Kindle

The enormous advances in the immunologic aspects of biotherapeutics and nanomedicines in the past two decades has necessitated an authoritative and comprehensive reference source that can be relied upon by immunologists, biomedical researchers, clinicians, pharmaceutical companies, regulators, venture capitalists, and policy makers alike. This text provides a thorough understanding of immunology, therapeutic potential, clinical applications, adverse reactions, and approaches to overcoming immunotoxicity of biotherapeutics and nanomedicines. It also tackles critical, yet often overlooked topics such as immune aspects of nano-bio interactions, current FDA regulatory guidances, complement activation-related pseudoallergy (CARPA), advances in nanovaccines, and immunogenicity testing of protein therapeutics.

Detection and Quantification of Antibodies to Biopharmaceuticals

Detection and Quantification of Antibodies to Biopharmaceuticals
Author: Michael G. Tovey
Publisher: John Wiley & Sons
Total Pages: 316
Release: 2011-07-12
Genre: Medical
ISBN: 1118075676

Download Detection and Quantification of Antibodies to Biopharmaceuticals Book in PDF, Epub and Kindle

The definitive book on the neutralization of recombinant biopharmaceuticals Recombinant biopharmaceuticals are an important tool for treating a range of illnesses; however, their efficacy can be severely impaired by their immunogenicity. When introduced into the body, these pharmaceuticals can cause the immune system to produce anti-drug antibodies (ADAs) that neutralize their effects. The first and only book to cover neutralization in connection with biopharmaceuticals and the measurement and application of neutralizing antibodies in modern medicine at any real length, Detection and Quantification of Antibodies to Biopharmaceuticals: Practical and Applied Considerations offers a comprehensive and in-depth look at all the principal aspects of the detection and quantification of antibodies that are essential to understanding and responding to the challenges they present. Bringing together a large-scale review of neutralization and biopharmaceuticals and the ability to measure, detect, and apply antibodies to modern science and medicine with international regulatory perspectives, the expectations of regulatory authorities, and the strengths and weaknesses of various assays, the book describes several novel ideas for detecting ADAs. Designed to serve as a resource for biopharmaceutical drug development, the book provides biotechnology companies and pharmaceutical drug development specialists, as well as non-experts, with key insights into the design, optimization, and qualification of assays, the establishment of sampling strategies, the choice of appropriate assay end-points, and data analysis for the detection and quantification of neutralizing antibodies.

Biosimilars and Interchangeable Biologics

Biosimilars and Interchangeable Biologics
Author: Sarfaraz K. Niazi
Publisher: CRC Press
Total Pages: 599
Release: 2018-10-30
Genre: Medical
ISBN: 149874348X

Download Biosimilars and Interchangeable Biologics Book in PDF, Epub and Kindle

What’s the Deal with Biosimilars? Biosimilars are gaining momentum as new protein therapeutic candidates that can help fill a vital need in the healthcare industry. The biological drugs are produced by recombinant DNA technology that allows for large-scale production and an overall reduction time in costs and development. Part of a two-volume set that covers varying aspects of biosimilars, Biosimilars and Interchangeable Biologics: Strategic Elements explores the strategic planning side of biosimilar drugs and targets issues surrounding biosimilars that are linked to legal matters. This includes principal patents and intellectual property, regulatory pathways, and concerns about affordability on a global scale. It addresses the complexity of biosimilar products, and it discusses the utilization of biosimilars and related biological drugs in expanding world markets. Of specific interest to practitioners, researchers, and scientists in the biopharmaceutical industry, this volume examines the science, technology, finance, legality, ethics, and politics of biosimilar drugs. It considers strategic planning elements that include an overall understanding of the history and the current status of the art and science of biosimilars, and it provides detailed descriptions of the legal, regulatory, and commercial characteristics. The book also presents a global strategy on how to build, take to market, and manage the next generation of biosimilars throughout their life cycle.

Biosimilarity

Biosimilarity
Author: Sarfaraz K. Niazi
Publisher: CRC Press
Total Pages: 488
Release: 2018-10-03
Genre: Medical
ISBN: 1315351374

Download Biosimilarity Book in PDF, Epub and Kindle

Summary: The focus of this book is on how the U.S. FDA will approve biosimilar drugs, as learned from recent approvals by the FDA. Understanding the limitations of the statutory limits and non-inferiority testing are presented as tools to obviate patient trials and minimize testing of immunogenicity. An in-depth scientific, mathematical and statistical view of the tools required to establish biosimilarity of biological drugs of different complexity -- a must for every developer of biosimilars. Features: First comprehensive analysis based on new guidelines and approval packages of several biosimilars Presents the first approach to challenge FDA in reducing or eliminating any testing in patients. Provides a comprehensive understanding of the U.S. statutory requirements vis-a-vis the regulatory guidelines Provides model CQA and Analytical Similarity testing protocols for cytokines and monoclonal antibodies Allow creation of a fast-to-market pathway to develop biosimilars

Handbook of Bioequivalence Testing

Handbook of Bioequivalence Testing
Author: Sarfaraz K. Niazi
Publisher: CRC Press
Total Pages: 1007
Release: 2014-10-29
Genre: Medical
ISBN: 1482226383

Download Handbook of Bioequivalence Testing Book in PDF, Epub and Kindle

As the generic pharmaceutical industry continues to grow and thrive, so does the need to conduct adequate, efficient bioequivalence studies. In recent years, there have been significant changes to the statistical models for evaluating bioequivalence. In addition, advances in the analytical technology used to detect drug and metabolite levels have m

Nonclinical Development of Novel Biologics, Biosimilars, Vaccines and Specialty Biologics

Nonclinical Development of Novel Biologics, Biosimilars, Vaccines and Specialty Biologics
Author: Lisa Plitnick
Publisher: Academic Press
Total Pages: 441
Release: 2013-06-27
Genre: Medical
ISBN: 0123948231

Download Nonclinical Development of Novel Biologics, Biosimilars, Vaccines and Specialty Biologics Book in PDF, Epub and Kindle

Nonclinical Development of Novel Biologics, Biosimilars, Vaccines and Specialty Biologics is a complete reference devoted to the nonclinical safety assessment of novel biopharmaceuticals, biosimilars, vaccines, cell and gene therapies and blood products. This book compares and contrasts these types of biologics with one another and with small molecule drugs, while incorporating the most current and essential international regulatory documents. Each section discusses a different type of biologic, as well as early characterization strategies, principles of study design, preclinical pharmacokinetics and pharmacodynamics and preclinical assays. An edited book that is authored by leading experts in the field, this comprehensive reference provides critical insights to all researchers involved in early through late stage biologics. Provides in-depth coverage of the process of nonclinical safety assessment and comprehensive reviews of each type of biopharmaceutical Contains the most pertinent international regulatory guidance documents for nonclinical evaluation Covers early de-risking strategies and designs of safety assessment programs for novel biopharmaceuticals and vaccines, as well as follow-on biologics or "biosimilars" A multi-authored book with chapters written by qualified experts in their respective fields